Introduction
A progressive accumulation of genetic changes in oncogenes and tumor suppressor genes leads to carcinogenesis (Bishop, 1991) . A major goal in cancer research is to identify early genetic changes that lead to tumorigenesis. The identi®cation of these changes can lead to the development of diagnostic tools for early detection and novel therapeutic approaches to treat this deadly disease more eectively. Pancreatic adenocarcinoma is the ®fth most common cancer (Boring et al., 1991) in the United States and fewer than 5% of the patients with this malignancy survive 5 years. High frequencies of allelic loss have been found on chromosome arms 1p (50%), 6p (50%), 6q (50%), 9p (76%), 17p (75%), 18q (88%), 21q (61%), and 22q (61%) in pancreatic adenocarcinomas (Seymour et al., 1994) . These allelic losses correspond to known genomic locations of tumor suppressor genes. DPC4, a candidate tumor suppressor gene at 18q21.1 has been shown to contain potentially inactivating mutations in six of 27 pancreatic adenocarcinomas (Hahn et al., 1996) . The frequency of chromosome 3p loss in pancreatic cancer has ranged from 13% in a report by Grin et al. (1995) to as high as 40% by Hahn et al. (1995) . However, we have found loss of 3p sequences outside of the FRA3B (3p14.2) region to be a relatively uncommon event in pancreatic cancer, (64% in 3p14.2 versus 8% outside of it) (Shridhar et al., 1996b) .
Deletion of DNA sequences within human chromosomal band 3p21 has been observed frequently both in lung cancer (Naylor et al., 1987; Kok et al., 1987; Brauch et al., 1987; Muira et al., 1990; Yokoyama et al., 1992) and renal cell carcinoma (Miller et al., 1989; Zbar et al., 1987; Kovacs et al., 1988; Kovacs and Kung, 1991; Yamakawa et al., 1991; Morita et al., 1991) suggesting that there is a tumor suppressor gene within this region. We have identi®ed a gene which contains an imperfect trinucleotide repeat that encodes a stretch of arginines. Because of the Arginine-Rich region, in this highly basic Protein, we have called the gene ARP (1). Although this gene showed no gross structural alterations in any sporadic renal cell carcinomas (RCC) or lung tumors, we found a specific mutation involving codon 50 in 10/21 renal tumors, 5/ 13 prostate tumors, 6/18 NSCLC samples, 9/22 breast tumors, and 5/21 head and neck carcinomas. (Shridhar et al., 1996 (Shridhar et al., , 1996a . The presence of this speci®c mutation in a variety of tumor types, and in one third of all tumors studied, suggests that this mutation is causal in these tumors, and has led us to analyse other cancers including pancreatic adenocarcinomas for corresponding mutations.
In this study we have identi®ed mutations in the ARP gene in 15/37 (41%) of the pancreatic ductal adenocarcinomas examined, with most showing a speci®c mutation involving codon 50.
Results
We sequenced seven subclones of DNA that was PCR ampli®ed from matched normal DNA sample from eight of the 37 pancreatic cancer patients. Three mutations observed in 56 subclones were randomly distributed and were all dierent. The error rate observed (mutations/nucleotide/cycle), 1 ± 2610
75
, is similar to what we reported for the same PCRampli®ed imperfect trinucleotide repeat region in normal lung samples (Shridhar et al., 1996a) .
We sequenced 188 subclones from the 37 pancreatic cancer samples. We detected nucleotide changes in 15 of the 37 samples (Table 1) . We believe 13 of them represent mutations present in the tumor cells themselves while two may be PCR artifacts. Eleven had a mutation involving codon 50: Four had the common ATG 50 ?AGG nucleotide substitution and three had the fairly common deletion of codon 50. However, in tumors 1, 2, 20, and 72 the ATG at codon 50 was replaced by ACG, GTG, AAG, and ATC, respectively.
In tumor samples 12 and 66, a mutation at codon 51 was observed in 3/5 and 6/6 sub-clones respectively. This mutation, AGG 51 ?AAG, (Arg?Lys) was not present in any of the normal samples and was not seen in any of the other cancers tested for mutations in this gene.
Other nucleotide changes were observed in two tumors. However, the frequency of these random changes, 1.6610 75 per nucleotide per cycle, roughly equals the frequency of mutations seen in the normal samples, and may be PCR induced artifacts. Table 1 lists all the mutations or artifactual changes seen in the subclones of the PCR-ampli®ed pancreatic tumor samples. Figure 1 shows three representative sequencing gels.
The 13 tumors in which mutations were seen in one or more sub-clones usually had one or more sub-clones with the wild-type sequence as well. Overall in these samples, there were 31 mutant and 31 wild-type subclones. This could be explained by the presence of contaminating normal tissue in the tumor samples. Other possible explanations are that only one copy of the gene has mutated, or that there is a mutation in the other copy in a dierent part of the gene than the region examined. Table 2 summarizes the location, stage, grade of the pancreatic ductal adenocarcinomas including the survival status of the 37 patients in this study. Of the 11 patients with mutations in codon 50, three patients had stage I tumors, seven patients had stage III, and one patient had a stage IV tumor. Of the four patients with no ATG 50 change, three had the stage III tumor type, while the fourth patient had stage I tumor type. The other patients (with no mutations in the ARP gene) also did not reveal any I  III  III  III  III  III  I  III  IV  IV  I  IV  III  III  III  I  IV  I  I  II  IV  III  IV  III  II  III  III  I  III  III  III  III  III  IV  III  III A subset (20/37) of the pancreatic tumors, including the tumors that had mutations in codon 50, were analysed for mutations in two other genes containing cryptic trinucleotide repeats (HEGR2 and FBNR). Four clones were sequenced per tumor sample. Very few of the tumor subclones had single trinucleotide slippages (4/80 for HEGR2 and 3/80 for FBNR), and these were randomly distributed. None had point mutations in any of the codons involving the cryptic repeat regions of these genes (data not shown).
Discussion
We previously detected mutations involving codon 50 in 10/21 RCCs, 8/20 lung cancers, 5/21 head and neck cancers, 9/22 breast cancers, and 5/13 prostate cancers (Shridhar et al., 1996 (Shridhar et al., , 1996a . These results with pancreatic cancers also show the importance of ARP codon 50 mutations in carcinogenesis. While the deletion of codon 50 and the ATG 50 ?AGG mutation account for 79% (49/62) of the mutations seen in these cancers, other nucleotide substitutions at codon 50 account for 10% (6/62) and mutations at codons 51, 53 and 56 for 11% (7/62) (Shridhar et al., 1996 (Shridhar et al., , 1996a .
We have stressed that the very common ATG 50 ?AGG transversion and the common ATG 50 deletion abolish a methionine residue and give rise to an uninterrupted string of AGG trinucleotides in the ARP gene and arginines in its predicted protein product (Shridhar et al., 1996) . The presence of four other ATG 50 nucleotide substitutions that replace methionine with four dierent amino acids other than arginine may indicate that the loss of this methionine residue is critical. The fact that codon 50 is the main target for mutations in a variety of cancers implicates this codon in the carcinogenic role of this gene. The ®nding of an AGG?AAG (Arg?Lys) mutation in the adjacent codon 51 in two tumors may serve to emphasize further the importance of this region. Mutations involving the two methionine codons nearby, ATG 53 and ATG 56 , have been seen not only in two pancreatic tumors but also in one renal cell cancer and one squamous cell carcinoma of the head and neck (Shridhar et al., 1996a) . Again neither of these two codons was changed in any of the control samples we have analysed (Shridhar et al., 1996 (Shridhar et al., , 1996a .
The frequency of the wild-type allele is 50% (31/62) in the 13 pancreatic tumor samples that had mutations in this region of the gene. We observed a similar frequency of subclones with the wild-type allele in the other tumor types that had mutations in the repeat region of this gene (Shridhar et al., 1996 (Shridhar et al., , 1996a . This is consistent with the notion that only a single copy of this gene is mutant in any cancer cell, but could simply re¯ect the presence of many normal cells in the tumor samples. However, previous analyses with cell lines derived from small cell lung carcinoma and squamous cell carcinoma of the head and neck revealed a similar frequency of sub-clones with the wild type sequence (Shridhar et al., 1996a) . This would suggest that only a single copy of the ARP gene is mutated in these cells. This result is compatible with the presumed role of ARP as an oncogene. Experiments are currently underway to test the eect of introducing the commonly observed codon 50 mutation into noncancerous cells that contain no mutations in the ARP gene.
The human early response 2 protein gene and ®bronectin receptor gene (Joseph et al., 1989; Argraves et al., 1987) , like the ARP gene contain cryptic trinucleotide repeats but these did not show a speci®c mutation in any of the 20 pancreatic adenocarcinomas examined. The frequency of single trinucleotide slippages in these two genes was similar to that of the random changes induced in normal tissue samples during PCR and no point mutations were detected in either gene in any of the 80 subclones tested. Thus not all cryptic trinucleotides in genes accumulate mutations in cancer cells.
Materials and methods
All the 37 tumors analysed were pancreatic ductal adenocarcinomas. None of the patients in this study had prior primary tumors. Paran curls of the tumors were obtained from the Detroit Medical Center, Harper Hospital (Detroit, MI). DNA from the paran curls was isolated using published procedures (Shridhar et al., 1996 (Shridhar et al., , 1996a . The corresponding normal DNA was obtained from histologically normal tissue surrounding the tumor. PCR ampli®cation, subcloning and sequencing of the imperfect trinucleotide repeat region of the ARP gene was as previously described (Shridhar et al., 1996) .
PCR ampli®cation and sequencing of two other genes with cryptic trinucleotide repeats
There are a number of other genes that contain cryptic trinucleotide repeats. We constructed PCR primers anking the cryptic repeats from two of these: the Human Early Growth Response 2 protein gene (HEGR2) (Joseph et al., 1989) , and the Fibronectin Receptor gene (FBNR) (Argraves et al., 1987) . A 190 bp fragment containing four GCA repeats followed by six GCC repeats was ampli®ed using primers HF (GGTAGCAGCTCAGCAGCAG) and HR (TGTCAGCTCGTCAGAGCG) from HEGR2. The imperfect repeat in this gene codes a stretch of 10 alanines within the open reading frame. A 219 bp fragment from FBNR containing the repeat (AC CCC CGC TCGTGCCG CT GCTGTTGCTGCTCGTGCC-GCCGCC) was ampli®ed using primers FF (CCGG-ACAGGGAAGAGCG) and FR (ACTCCACTGAGA-ATCCGAAG). The imperfect repeat in this gene coded the following stretch of amino acids-PL 2 PL 6 P 4 . PCR conditions were as follows: Initial denaturation for 2' at 948C followed by 35 cycles of 948C-45 s, 558C-1', 728C-30 s, with a ®nal extension at 728C for 5 min. The PCR products were resolved on a 2% agarose gel, gene cleaned (Bio 101), and subcloned into a TA cloning vector according to the manufacturers' instructions (Invitrogen). Cycle sequencing of the subclones were as previously described (Shridhar et al., 1996) .
